269 related articles for article (PubMed ID: 26202958)
1. Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature.
Arizmendez NP; Rudmik L; Poetker DM
Int Forum Allergy Rhinol; 2015 Nov; 5(11):1042-7. PubMed ID: 26202958
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia: An Evidence-based Review.
Halderman AA; Ryan MW; Marple BF; Sindwani R; Reh DD; Poetker DM
Am J Rhinol Allergy; 2018 Jul; 32(4):258-268. PubMed ID: 29745243
[TBL] [Abstract][Full Text] [Related]
3. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J
Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
Parambil JG; Woodard TD; Koc ON
Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965
[TBL] [Abstract][Full Text] [Related]
5. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].
Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K
Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875
[TBL] [Abstract][Full Text] [Related]
6. Plasma VEGF - a candidate biomarker for response to treatment with bevacizumab in HHT patients.
Liu DT; Frohne A; Koenighofer M; Frei K; Lucas T; Riss D; Parzefall T
Rhinology; 2020 Feb; 58(1):18-24. PubMed ID: 31681913
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab as Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Literature Review.
Kini SD; Yiu DW; Weisberg RA; Davila JF; Chelius DC
Ann Otol Rhinol Laryngol; 2019 May; 128(5):467-471. PubMed ID: 30693788
[TBL] [Abstract][Full Text] [Related]
8. Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series.
Rosenberg T; Fialla AD; Kjeldsen J; Kjeldsen AD
Rhinology; 2019 Aug; 57(4):242-251. PubMed ID: 30907391
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia.
Kanellopoulou T; Alexopoulou A
Expert Opin Biol Ther; 2013 Sep; 13(9):1315-23. PubMed ID: 23815519
[TBL] [Abstract][Full Text] [Related]
10. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia.
Epperla N; Hocking W
Clin Med Res; 2015 Mar; 13(1):32-5. PubMed ID: 24667223
[TBL] [Abstract][Full Text] [Related]
11. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.
Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ
J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646
[TBL] [Abstract][Full Text] [Related]
12. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab.
Fleagle JM; Bobba RK; Kardinal CG; Freter CE
Am J Med Sci; 2012 Mar; 343(3):249-51. PubMed ID: 22227516
[TBL] [Abstract][Full Text] [Related]
13. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study.
Al-Samkari H; Kasthuri RS; Parambil JG; Albitar HA; Almodallal YA; Vázquez C; Serra MM; Dupuis-Girod S; Wilsen CB; McWilliams JP; Fountain EH; Gossage JR; Weiss CR; Latif MA; Issachar A; Mei-Zahav M; Meek ME; Conrad M; Rodriguez-Lopez J; Kuter DJ; Iyer VN
Haematologica; 2021 Aug; 106(8):2161-2169. PubMed ID: 32675221
[TBL] [Abstract][Full Text] [Related]
14. Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding.
Iyer VN; Apala DR; Pannu BS; Kotecha A; Brinjikji W; Leise MD; Kamath PS; Misra S; Begna KH; Cartin-Ceba R; DuBrock HM; Krowka MJ; O'Brien EK; Pruthi RK; Schroeder DR; Swanson KL
Mayo Clin Proc; 2018 Feb; 93(2):155-166. PubMed ID: 29395350
[TBL] [Abstract][Full Text] [Related]
15. Sclerotherapy for Hereditary Hemorrhagic Telangiectasia-Related Epistaxis: A Systematic Review.
Thiele B; Abdel-Aty Y; Marks L; Lal D; Marino M
Ann Otol Rhinol Laryngol; 2023 Jan; 132(1):82-90. PubMed ID: 35152768
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F
JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517
[TBL] [Abstract][Full Text] [Related]
17. Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review.
Stokes P; Rimmer J
Rhinology; 2018 Mar; 56(1):3-10. PubMed ID: 29166422
[TBL] [Abstract][Full Text] [Related]
18. A lack of race and ethnicity data in the treatment of hereditary hemorrhagic telangiectasia: a systematic review of intravenous bevacizumab efficacy.
Galiatsatos P; Wilson C; O'Brien J; Gong AJ; Angiolillo D; Johnson J; Myers C; Strout S; Mathai S; Robinson G; Rowan NR; Weiss CR
Orphanet J Rare Dis; 2022 Jun; 17(1):220. PubMed ID: 35698080
[TBL] [Abstract][Full Text] [Related]
19. Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report.
Villanueva B; Iriarte A; Torres-Iglesias R; Muñoz Bolaño M; Cerdà P; Riera-Mestre A
Medicina (Kaunas); 2023 Aug; 59(9):. PubMed ID: 37763652
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report.
Ospina FE; Echeverri A; Posso-Osorio I; Jaimes L; Gutierrez J; Tobón GJ
Colomb Med (Cali); 2017 Jun; 48(2):88-93. PubMed ID: 29021642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
